Vorsetuzumab mafodotin
(Redirected from Vorsetuzumab)
Monoclonal antibody | |
---|---|
Type | ? |
Source | Humanized (from mouse) |
Target | CD70 |
Clinical data | |
Other names | SGN-75 |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6476H10006N1726O2028S50(C49H78N6O11)3-5 |
Molar mass | 150 kg/mol |
Vorsetuzumab mafodotin (SGN-75) is an antibody-drug conjugate (ADC) directed to the protein CD70 designed for the treatment of cancer.[1] It is a humanized monoclonal antibody, vorsetuzumab, conjugated with noncleavable monomethyl auristatin F (MMAF), a cytotoxic agent.[citation needed]
This drug was developed by Seattle Genetics, Inc. The drug completed phase I clinical trials for renal cell carcinoma,[2] but development was discontinued in 2013.[3] No reason was given but SG plan to start clinical trials of SGN-CD70A in 2014.[3]
References
Categories:
- All articles with dead external links
- Articles with dead external links from January 2024
- Articles with permanently dead external links
- Articles with short description
- Short description matches Wikidata
- Drugs not assigned an ATC code
- Drugs with non-standard legal status
- Chemicals that do not have a ChemSpider ID assigned
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without InChI source
- Articles containing unverified chemical infoboxes
- Drugs that are a monoclonal antibody
- All articles with unsourced statements
- Articles with unsourced statements from February 2023
- All stub articles
- Monoclonal antibody stubs
- Monoclonal antibodies for tumors
- Antibody-drug conjugates
- Experimental cancer drugs